. 2018 Apr 5;7(8):e008150. doi: 10.1161/JAHA.117.008150

Table 3.

Number of Events, Crude and Adjusted Event Rates Among 4 Treatment Groups

	Apixaban (n=5843)			Dabigatran (n=20 079)			Rivaroxaban (n=27 777)			Warfarin (n=19 375)
	Events	Crude Incidence^a	Adjusted Incidence^b	Events	Crude Incidence^a	Adjusted Incidence^b	Events	Crude Incidence^a	Adjusted Incidence^b	Events	Crude Incidence^a	Adjusted Incidence^b
Ischemic stroke/systemic embolism	100	2.26	2.26	854	2.74	2.90	977	2.84	3.00	929	3.26	3.55
Ischemic stroke	91	2.06	2.06	747	2.40	2.56	870	2.53	2.65	793	2.79	3.05
Acute myocardial infarction	23	0.52	0.52	134	0.43	0.47	146	0.42	0.43	177	0.62	0.61
All‐cause mortality	319	7.22	7.22	1575	5.05	6.69	2051	5.97	6.57	2588	9.09	10.96
Intracranial hemorrhage	31	0.70	0.70	233	0.75	0.70	272	0.79	0.74	378	1.33	1.41
Major gastrointestinal bleeding	28	0.63	0.63	362	1.16	1.28	394	1.15	1.07	444	1.56	1.65
All major bleeding	67	1.52	1.52	625	2.01	2.12	707	2.06	1.97	855	3.00	3.25

Events divided by 100 person‐years.

Inverse probability of treatment weighted to apixaban and expressed as population average treatment rates per 100 years.